Satellos to Present New SAT-3247 Clinical Data at ICNMD

Satellos Bioscience Inc. announced it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy, from July 7-11, 2026. The presentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD study. Additionally, the company's Chief Medical Officer will deliver a Showcase Theatre presentation on advancing muscle repair with SAT-3247, an investigational oral drug for Duchenne muscular dystrophy and other degenerative muscle diseases.